AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19640384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma C-reactive protein
Number of subjects: 141
Study 19640384 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR
Number of subjects: 141
Study 19640384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma von Willebrand factor and soluble vascular adhesion molecule-1
Number of subjects: 141
Study 17251174 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft
Number of subjects: 33
Study 17251174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft
Number of subjects: 33
Study 17251174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 15167309 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 2 mg + norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 28
Study 15167309 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene HCL 60 mg
Number of subjects: 28
Study 12518494 — intervention group
Group type: EXPERIMENTAL
Intervention: Discus Dental Zoom! Chairside System (25% hydrogen peroxide whitening gel)
Number of subjects: 22
Study 12518494 — intervention group
Group type: COMPARATOR
Intervention: Opalescence Xtra Boost Kit (38% hydrogen peroxide whitening gel)
Number of subjects: 22
Study 9811286 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic extract (Kwai, 300 mg, 3 times a day)
Number of subjects: 30
Study 7815239 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding with a whole protein‐based formula (Nutrison Standard, Nutricia)
Number of subjects: 19
Study 7815239 — intervention group
Group type: COMPARATOR
Intervention: High‐dose corticosteroids
Number of subjects: 19
Study 2576361 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride 2 mg/d
Number of subjects: 48
Study 2576361 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride 4 mg/d
Number of subjects: 48
Study 2576361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2576361 — intervention group
Group type: EXPERIMENTAL
Intervention: Picumast dihydrochloride with 0.5% blood alcohol concentration
Number of subjects: 48
Study 778344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 42
Study 778344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 42
Study 29570574 — intervention group
Group type: EXPERIMENTAL
Intervention: PJT-B (Plyometric Jump Training Before Soccer Training)
Number of subjects: 38
Study 29570574 — intervention group
Group type: EXPERIMENTAL
Intervention: PJT-A (Plyometric Jump Training After Soccer Training)
Number of subjects: 38
Study 29570574 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 38
Study 29273455 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook use
Number of subjects: 104
Study 29273455 — intervention group
Group type: COMPARATOR
Intervention: Sitting quietly with the option of reading electronic magazines (Control)
Number of subjects: 104
Study 27881709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin use in patients with diabetes mellitus (n = 115)
Number of subjects: 1958
Study 27881709 — intervention group
Group type: COMPARATOR
Intervention: Non-users of metformin (DM patients without metformin use and non-DM patients)
Number of subjects: 1958
Study 24351803 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnea hypopnea index (AHI)
Number of subjects: 298
Study 24351803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI)
Number of subjects: 298
Study 22982906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient counseling
Number of subjects: 50
Study 22982906 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 50
Study 20163275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (1 to 3 mg/24 h)
Number of subjects: 0
Study 20163275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 0
Study 16450820 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic wrap fixation method
Number of subjects: 0
Study 16450820 — intervention group
Group type: COMPARATOR
Intervention: Gauze bandage fixation method
Number of subjects: 0
Study 16450820 — intervention group
Group type: COMPARATOR
Intervention: Adhesive bandage fixation method
Number of subjects: 0
Study 16450820 — intervention group
Group type: COMPARATOR
Intervention: Coban wrap fixation method
Number of subjects: 0
Study 12604873 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise training program (group W, n=15)
Number of subjects: 30
Study 12604873 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C, n=15)
Number of subjects: 30
Study 10985319 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal social marketing intervention
Number of subjects: 1402
Study 8626365 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone, 100 mg b.i.d. starting dose, adjusted to 300-500 mg daily
Number of subjects: 0
Study 8626365 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 0
Study 1425394 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g dextrose
Number of subjects: 48
Study 1425394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2866168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet (L-DOPA plus carbidopa) with haloperidol
Number of subjects: 1
Study 2866168 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol-placebo
Number of subjects: 1
Study 29025085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg sublingual buprenorphine
Number of subjects: 38
Study 29025085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 27117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg Q3W
Number of subjects: 449
Study 27117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q3W
Number of subjects: 449
Study 27117531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg Q2W
Number of subjects: 449
Study 24342689 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitic acid (PA; 2% of diet dry matter)
Number of subjects: 32
Study 22719063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vdrive robotic system for remote navigation of circular mapping catheters
Number of subjects: 94
Study 20617288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (ACE-inhibitor) for 6 months
Number of subjects: 100
Study 17852925 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (r-hGH) 4 mg daily
Number of subjects: 20
Study 15832628 — intervention group
Group type: EXPERIMENTAL
Intervention: Similarity-guided retrieval procedure
Number of subjects: 0
Study 15832628 — intervention group
Group type: EXPERIMENTAL
Intervention: Foil memory test procedure
Number of subjects: 0
Study 12450890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (5 x 10(7) colony-forming units/mL) in a rose-hip drink, 400 mL/d for 6 weeks
Number of subjects: 36
Study 12450890 — intervention group
Group type: COMPARATOR
Intervention: Control group (rose-hip drink without bacteria), 400 mL/d for 6 weeks
Number of subjects: 36
Study 10496829 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational interviewing (one interview)
Number of subjects: 523
Study 10496829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive motivational interviewing (six interviews over 12 weeks)
Number of subjects: 523
Study 10496829 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive (30 vouchers for leisure facilities) with intensive motivational interviewing
Number of subjects: 523
Study 10496829 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 523
Study 10496829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (all combined interventions)
Number of subjects: 523
Study 8630585 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 17.8 ± 2.7 ppm
Number of subjects: 16
Study 8630585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (PGI2) at 7.5 ± 2.5 ng/kg min
Number of subjects: 16
Study 8630585 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 16
Study 8630585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized prostacyclin (PGI2)
Number of subjects: 16
Study 1746300 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-administered genogram (PAGE)
Number of subjects: 189
Study 1746300 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered genogram (SAGE)
Number of subjects: 189
Study 1746300 — intervention group
Group type: COMPARATOR
Intervention: No genogram (Control)
Number of subjects: 189
Study 1746300 — intervention group
Group type: COMPARATOR
Intervention: Baseline group (without genograms)
Number of subjects: 189
Study 6121579 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg lormetazepam
Number of subjects: 8
Study 6121579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg flunitrazepam
Number of subjects: 8
Study 6121579 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 8
Study 6121579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31023281 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate PrEP
Number of subjects: 436
Study 27875076 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental resource empowerment score (mean 2.95, SD 0.56; range 1-4)
Number of subjects: 721
Study 27875076 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental resource empowerment score
Number of subjects: 721
Study 26219141 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Slow Maxillary Expansion Appliance (MSMEA)
Number of subjects: 40
Study 26219141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24411524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hemisphere tDCS (anodal over left S1, cathodal over right S1)
Number of subjects: 9
Study 24411524 — intervention group
Group type: COMPARATOR
Intervention: Uni-hemisphere tDCS (anodal over left S1, cathodal over contralateral supraorbital front)
Number of subjects: 9
Study 24411524 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (1mA, 30s)
Number of subjects: 9
Study 23051949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 4133
Study 23051949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4133
Study 19678927 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast Conservative Therapy (BCT)
Number of subjects: 100
Study 19678927 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 100
Study 17181851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (Advice Group)
Number of subjects: 183
Study 17181851 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no dietary advice)
Number of subjects: 183
Study 15880962 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (X group)
Number of subjects: 123
Study 15880962 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (G group)
Number of subjects: 123
Study 15880962 — intervention group
Group type: COMPARATOR
Intervention: No gum (C group)
Number of subjects: 123
Study 12458352 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir or oseltamivir
Number of subjects: 56
Study 12458352 — intervention group
Group type: COMPARATOR
Intervention: Control group (before neuraminidase inhibitors)
Number of subjects: 56
Study 9792309 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome, 5 mg/kg/d)
Number of subjects: 66
Study 9792309 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (AmB, 1 mg/kg/d)
Number of subjects: 66
Study 10513074 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine at 5 micrograms/Kg/min
Number of subjects: 14
Study 10513074 — intervention group
Group type: COMPARATOR
Intervention: Amrinone at 5 micrograms/Kg/min
Number of subjects: 14
Study 1675649 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion cleansing
Number of subjects: 38
Study 1675649 — intervention group
Group type: COMPARATOR
Intervention: Liquid soap
Number of subjects: 38
Study 6330425 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy using a nonproprietary zinc dialysate
Number of subjects: 12
Study 30957382 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution manometry (HRM)
Number of subjects: 163
Study 26796396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1260
Study 26796396 — intervention group
Group type: COMPARATOR
Intervention: Low RWT (<0.24)
Number of subjects: 1260
Study 26796396 — intervention group
Group type: COMPARATOR
Intervention: Decrease in RWT
Number of subjects: 1260
Study 25245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (IVL) - 2% intravenously (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Number of subjects: 60
Study 25245767 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural lidocaine analgesia (LEA) - lidocaine epidurally (1.5 mg/kg bolus, 2 mg/kg/h infusion)
Number of subjects: 60
Study 25245767 — intervention group
Group type: COMPARATOR
Intervention: Control group - normal saline (NS) both intravenously and epidurally
Number of subjects: 60
Study 22234019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous low-dose ketamine (0.1 mg/kg as a preincisional bolus followed by a continuous infusion of 0.05 mg/kg/h)
Number of subjects: 60
Study 22234019 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study 19661813 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG spectral power during sleep in GERD patients
Number of subjects: 17
Study 19661813 — intervention group
Group type: COMPARATOR
Intervention: Conventional sleep stage summaries
Number of subjects: 17
Study 17414140 — intervention group
Group type: EXPERIMENTAL
Intervention: Anoplasty for perineal fistula
Number of subjects: 24
Study 17414140 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 24
Study 15895327 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled telephone intervention (n=85, 79 completed outcome assessment)
Number of subjects: 171
Study 15895327 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=86, 78 completed outcome assessment)
Number of subjects: 171
Study 11903374 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0
Study 11903374 — intervention group
Group type: COMPARATOR
Intervention: Nasal surgery (Control)
Number of subjects: 0
Study 9613405 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg administered the evening and morning before surgery
Number of subjects: 0
Study 9613405 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8512909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular and oral ketorolac
Number of subjects: 0
Study 8512909 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 0
Study 8512909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3450519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine therapy for 2 and 14-16 weeks
Number of subjects: 42
Study 3450519 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine therapy
Number of subjects: 42
Study 29467138 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (provider education, patient decision aid and navigation support)
Number of subjects: 100
Study 29467138 — intervention group
Group type: COMPARATOR
Intervention: Usual care (consultation and referral, if requested)
Number of subjects: 100
Study 28002347 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq DL videolaryngoscope
Number of subjects: 90
Study 28002347 — intervention group
Group type: COMPARATOR
Intervention: McGrath Series 5 videolaryngoscope
Number of subjects: 90
Study 25491116 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 0
Study 25491116 — intervention group
Group type: COMPARATOR
Intervention: 0.05% desonide cream
Number of subjects: 0
Study 22732367 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable interference screw only (group I)
Number of subjects: 80
Study 22732367 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable interference screw supplemented by a post-tie using a washer screw (group II)
Number of subjects: 80
Study 20507651 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-pressure/variable-frequency HFCWC
Number of subjects: 16
Study 20507651 — intervention group
Group type: COMPARATOR
Intervention: Lower-pressure/mid-frequency HFCWC
Number of subjects: 16
Study 18257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (Hegu (LI 4) and Taichong (LR 3))
Number of subjects: 440
Study 18257177 — intervention group
Group type: COMPARATOR
Intervention: Prozac (20 mg/d)
Number of subjects: 440
Study 18257177 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint needling
Number of subjects: 440
Study 18257177 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 440
Study 18257177 — intervention group
Group type: COMPARATOR
Intervention: Prozac
Number of subjects: 440
Study 15678251 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical liposomal heparin spraygel (LHSG) (Lipohep Forte Spraygel, 4 puffs of 458 IU tid, n = 22)
Number of subjects: 46
Study 15678251 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH) (Clexane 40 mg once a day, n = 24)
Number of subjects: 46
Study 12790214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg + neostigmine 25 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 2)
Number of subjects: 45
Study 12790214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg + neostigmine 50 microg in dextrose 5%, 1 mL, total volume 3 mL (Group 3)
Number of subjects: 45
Study 12790214 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 10 mg + dextrose 5%, 1 mL, total volume 3 mL (Group 1)
Number of subjects: 45
Study 10376255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate in gel-forming solution
Number of subjects: 12
Study 10376255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8704690 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomagnetic CD4+ and CD8+ cell depletion with cyclosporine as GVHD prophylaxis
Number of subjects: 15
Study 8704690 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine as GVHD prophylaxis
Number of subjects: 15
Study 10895735 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva substitutes
Number of subjects: 0
Study 3900727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine (400 mg)
Number of subjects: 6024
Study 3900727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 6024
Study 31050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Women identifying as refugees
Number of subjects: 1335
Study 31050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Women from other conflict-affected backgrounds
Number of subjects: 1335
Study 31050785 — intervention group
Group type: EXPERIMENTAL
Intervention: Women born in the host nation
Number of subjects: 1335
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vulvar LSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vulvar HSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vaginal LSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: HPV genotypes (6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) detected in vaginal HSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Cervical lesions in females with vulvar lesions
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Cervical lesions in females with vaginal lesions
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Cervical lesions in females with vaginal or vulvar lesions
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vulvar LSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vulvar HSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vaginal LSILs
Number of subjects: 8798
Study 29995724 — intervention group
Group type: COMPARATOR
Intervention: Common HPV genotypes causing cervical cancer and anogenital warts in vaginal HSILs
Number of subjects: 8798
Study 26716580 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV XR 2000 mg/day (mean daily dose 2131 mg/day)
Number of subjects: 190
Study 26716580 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV XR monotherapy
Number of subjects: 190
Study 23764865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 366
Study 23764865 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation plus pressure support ventilation (SIMV-PSV)
Number of subjects: 366
Study 23008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course (SC) radiotherapy: 5 × 5 Gy in 1 week, early surgery, and six courses of adjuvant chemotherapy
Number of subjects: 326
Study 23008301 — intervention group
Group type: COMPARATOR
Intervention: Long-course (LC) chemoradiation: 50.4 Gy, 1.8 Gy/fraction, in 5.5 weeks, with continuous infusional fluorouracil 225 mg/m(2) per day, surgery in 4 to 6 weeks, and four courses of chemotherapy
Number of subjects: 326
Study 23008301 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course (SC) radiotherapy
Number of subjects: 326